Yin-Goen Q, Dale J, Yang W-L, Phan J, Moffitt R, Petros J A, Datta M W, Amin M B, Wang M D, Young A N
Department of Pathology & Laboratory Medicine, Emory University School of Medicine, Atlanta, GA, USA.
Histol Histopathol. 2006 Mar;21(3):325-39. doi: 10.14670/HH-21.325.
Kidney neoplasms are classified by light microscopy using the World Health Organization (WHO) system. The WHO system defines histopathologic tumor subtypes with distinct clinical behavior and underlying genetic mutations. In adults, the common malignant subtypes are variants of renal cell carcinoma (RCC). Histopathologic classification is critical for clinical management of RCC, but is becoming more complex with recognition of novel tumor subtypes, development of procedures yielding small diagnostic biopsies, and emergence of molecular therapies directed at tumor gene activity. Therefore, classification systems based on gene expression are likely to become essential for diagnosis, prognosis and treatment of kidney tumors. Recent DNA microarray studies have shown that clinically relevant renal tumor subtypes are characterized by distinct gene expression profiles, which are useful for discovery of novel diagnostic and prognostic biomarkers. In this review, we summarize the WHO classification system for renal tumors, general applications of microarray technology in cancer research, and specific microarray studies that have advanced knowledge of renal tumor diagnosis, prognosis, therapy and pathobiology.
肾肿瘤通过使用世界卫生组织(WHO)系统的光学显微镜进行分类。WHO系统定义了具有不同临床行为和潜在基因突变的组织病理学肿瘤亚型。在成人中,常见的恶性亚型是肾细胞癌(RCC)的变体。组织病理学分类对于RCC的临床管理至关重要,但随着新肿瘤亚型的识别、产生小诊断活检的程序的发展以及针对肿瘤基因活性的分子疗法的出现,其变得越来越复杂。因此,基于基因表达的分类系统可能对肾肿瘤的诊断、预后和治疗至关重要。最近的DNA微阵列研究表明,临床相关的肾肿瘤亚型具有独特的基因表达谱,这对于发现新的诊断和预后生物标志物很有用。在本综述中,我们总结了肾肿瘤的WHO分类系统、微阵列技术在癌症研究中的一般应用,以及推进了肾肿瘤诊断、预后、治疗和病理生物学知识的具体微阵列研究。